- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07616024
Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction (INSIGHT-STEMI)
Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
This study is a prospective, multicenter, randomized controlled, superiority clinical trial. Eligible subjects who meet the inclusion/exclusion criteria will be randomly assigned in a 1:1 ratio to either the IVUS-guided strategy (experimental group) or the conventional coronary angiography-guided strategy (control group). The study plans to enroll at least 2488 subjects, with 1244 subjects in each of the experimental and control groups. Zhongshan Hospital, Fudan University serves as the lead center. A competitive enrollment approach will be adopted, with the number of cases enrolled by the lead center not exceeding 50% of the total sample size.
In the IVUS group, intravascular ultrasound (IVUS) will be used for guidance; the use of high-frequency intravascular ultrasound (resolution ≥ 50 MHz) is encouraged, though not mandatory.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Chenguang Li, Doctor
- Numéro de téléphone: +8613816767665
- E-mail: li.chenguang@zs-hospital.sh.cn
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200032
- Zhongshan hospital
-
Chercheur principal:
- Junbo Ge, Doctor
-
Contact:
- Chenguang Li, Doctor
- Numéro de téléphone: +8613816767665
- E-mail: li.chenguang@zs-hospital.sh.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion criteria
- Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy;
- Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI);
- Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form;
- The IVUS catheter is expected to pass through the target lesion to complete the examination.
Exclusion Criteria
- Patients with cardiogenic shock or severe heart failure (Killip class IV);
- Patients who have previously undergone coronary artery bypass grafting (CABG);
- Patients with coma or disturbance of consciousness;
- Patients who are expected to be intolerant to long-term antiplatelet therapy;
- Pregnant women;
- Life expectancy < 1 year;
- Currently participating in another drug/device clinical trial and not having reached the primary endpoint;
- Poor compliance, expected to be unable to complete follow-up.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: IVUS group
In the experimental group, after the guidewire passes through the lesion, IVUS is used to guide the primary PCI procedure.
|
a catheter equipped with an ultrasound transducer is advanced over a guidewire into the vessel lumen distal to the target coronary lesion.
Then, while slowly withdrawing the catheter, 360-degree cross-sectional images of the vessel are acquired to accurately measure lumen dimensions, assess plaque characteristics, select an appropriately sized stent, and confirm that after stent implantation the stent is fully apposed, well expanded, and free of vascular complications.
Autres noms:
|
|
Autre: CAG group
In the control group, after the guidewire passes through the lesion, coronary angiography is used to guide the primary PCI procedure
|
A catheter is inserted through a peripheral artery (e.g., femoral or radial artery) and advanced to the ostium of the coronary arteries under fluoroscopic guidance.
Once positioned, contrast medium is injected while X-ray images are acquired to visualize the coronary artery lumen and detect any stenoses or occlusions.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Primary target vessel failure (TVF) rate
Délai: 1 year
|
defined as the composite endpoint of cardiac death, ischemia-driven target vessel revascularization, and target vessel-related myocardial infarction.
|
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Lesion success rate
Délai: Perioperative
|
Lesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
|
Perioperative
|
|
Clinical success rate
Délai: Pre-discharge
|
Lesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
|
Pre-discharge
|
|
Mortality rate
Délai: 1 Year
|
Includes cardiovascular death, non-cardiovascular death, and death of undetermined cause
|
1 Year
|
|
Incidence of myocardial infarction
Délai: 1 year
|
includes periprocedural myocardial infarction as defined by SCAI and spontaneous myocardial infarction (infarct-related artery-related vs. non-infarct-related artery-related; culprit lesion-related vs. non-culprit lesion-related)
|
1 year
|
|
Revascularization
Délai: 1 year
|
includes ischemia-driven and non-ischemia-driven revascularization, revascularization of infarct-related and non-infarct-related arteries, revascularization of culprit and non-culprit lesions, revascularization of target vessels and non-target vessels, and revascularization of target lesions and non-target lesions
|
1 year
|
|
Stent thrombosis
Délai: 1 year
|
Academic Research Consortium
|
1 year
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Junbo Ge, Doctor, Fudan University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies cardiaques
- Infarctus
- Nécrose
- Ischémie myocardique
- Infarctus du myocarde
- Ischémie
- Conditions pathologiques, signes et symptômes
- Infarctus du myocarde avec sus-décalage du segment ST
- Techniques et procédures de diagnostic
- Diagnostic
- Procédures chirurgicales, opératoires
- Procédures chirurgicales mini-invasives
- Imagerie diagnostique
- Échographie
- Échographie interventionnelle
Autres numéros d'identification d'étude
- B2025-555
- ChiCTR2600124260 (Autre identifiant: Chinese Clinical Trail Registry)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .